Highlights newsletter 1
This newsletter presents you the following key sessions:
1. VIDEO-INTERVIEW: Brian Hill, MD, PhD, Taussig Cancer Institute, Cleveland Clinic, Ohio explains if maintenance
rituximab after frontline therapy with bendamustine-rituximab (BR) was of any benefit in 640 FL patients
across 13 US academic medical centers
6. Update of ALCANZA trial: confirmed superior clinical activity of brentuximab vedotin in patients with
CD30-positive cutaneous T-cell lymphoma compared to methotrexate or bexarotene